Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised, 4th edn. Washington, DC: American Psychiatric Association, 2000
   Google Scholar
• American Psychiatric Association: Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd edn. Arlington, VA: American Psychiatric Association, 2004
   Google Scholar
• Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003;26:25-40
   PubMed Web of Science ®Google Scholar
• Schizophrenia 12 month prevalence. Mental Health Information. National Institute of Mental Health. Bethesda, MD: Available at www.nimh.nih.gov/statistics/1SCHIZ.shtml
   Google Scholar
• Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia—1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:196-205
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi I, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
   PubMed Web of Science ®Google Scholar
• Malla AK, Norman RM, Voruganti LP. Improving outcome in schizophrenia: the case for early intervention. CMAJ 1999;160:843-6
   PubMed Web of Science ®Google Scholar
• Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med 2011;123:153-62
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Slade EP, Medoff DR, et al. Time to discontinuation of first-and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophr Res 2011 May 14 [Epub ahead of print]. doi:10.1016/j.schres.2011.04.028
   Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29
   PubMed Web of Science ®Google Scholar
• McCreadie RG, Wiles D, Grant S, et al. The Scottish first episode of schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand 1989;80:597-602
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16:473-84
   PubMed Web of Science ®Google Scholar
• Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. Erratum in N Engl J Med 2010;363:1092-3
   PubMed Web of Science ®Google Scholar
• Emsley R, Medori R, Koen L, et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008;28:210-3. Erratum in J Clin Psychopharmacol 2008;28:624
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Schooler NR, Weedon JC, et al. A randomized controlled trial of long-acting injectable respiridone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009;70:1397-406
   PubMed Web of Science ®Google Scholar
• Girardi P, Serafini G, Pompili M, et al. Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Pharmacopsychiatry 2010;43:66-72
   PubMed Web of Science ®Google Scholar
• Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12:317-24
   PubMedGoogle Scholar
• Macfadden W, Bossie CA, Turkoz I, et al. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psychopharmacol 2010;25:75-82
   PubMed Web of Science ®Google Scholar
• Samtani M, Gopal S, Sliwa JK, et al. Switching to paliperidone palmitate from other antipsychotics: guidance based on pharmacokinetic modeling and simulation. New Clinical Drug Evaluation Unit Meeting, June 29-July 2, 2009; Hollywood, FL. Accessed September 28, 2009, http://208.81.106.111/Poster%20Abstract%20Book%20Final.pdf
   Google Scholar
• Samtani M, Sliwa JK, Haskins JT, et al. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation. J Pharm Pract 2009;22:216-17
   Google Scholar
• Samtani MN. Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly formulation of an atypical antipsychotic. Clin Pharmacokinet 48:585-600
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235-44. Erratum in J Clin Psychopharmacol. 2010;30:364
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116:107-17. Epub 2009 Dec 2
   PubMed Web of Science ®Google Scholar
• Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010 Jul 8 [E-pub ahead of print]. doi: 10.1177/0269881110372817
   Google Scholar
• Agresti A. An Introduction to Categorical Data Analysis. New York: John Wiley & Sons, 1996
   Google Scholar
• Stokes M, Davis C, Koch G. Categorical Data Analysis Using the SAS® System, 2nd edn. Cary, NC: SAS Institute, Inc, 2000
   Google Scholar
• Owen, RT. Olanzapine: a review of rapid and long-acting parenteral formulations. Drugs Today (Barc) 2010;46:173-81
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011 Mar 1. [Epub ahead of print]. doi: 10.1176/appi.ajp.2011.10081224
   Google Scholar